Collectively, these results manifested that low expression of PD-L1 in K562 could be enhanced by the upregulation of KEL and perhaps provided possible checkpoint inhibitor therapy strategy for AEL patients. This evidence concerns the gene CD274 and acute erythroid leukemia.